Breast Cancer Clinical Trial
— DIGNITYOfficial title:
A Phase I/II Study Evaluating the Maximum Tolerated Dose, Bioequivalence/Pharmacokinetics, Safety, and Efficacy of Hyperthermia and ThermoDox (Lyso-Thermosensitive Liposomal Doxorubucin) in Patients With Local-Regional Recurrent Breast Cancer.
Verified date | January 2017 |
Source | Celsion |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a research study to evaluate the effects of ThermoDox in combination with therapeutic heating of the chest wall in the treatment of recurrent regional breast cancer. The purpose of this study is to evaluate the bioequivalence of ThermoDox and measure efficacy in recurrent chest wall patients.
Status | Completed |
Enrollment | 17 |
Est. completion date | June 2016 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Histologically documented recurrent/metastatic adenocarcinoma of the breast with a recurrence on the chest wall (or its overlying skin): - Subjects with ulcerative chest wall disease defined as non-healing wounds consistent with cancer are eligible. - Subjects with prior skin changes consistent with inflammatory breast carcinoma are eligible. - Breast carcinoma for medical reasons not being resected 2. Tumor thickness must be clinically indicated for hyperthermia therapy, as measured by clinical exam or imaging studies (CT or MRI). The target local tumor lesion(s) must be able to be covered within two hyperthermia fields of treatment. 3. Disease that has progressed despite other available standard treatment options, based on what is clinically indicated according to the investigator's clinical and medical judgment, including: - One or more radiation treatment(s) to the chest wall or breast up to a maximum prior dose of 12,000 cGy in the hyperthermia field (not administered less than 28 days prior to enrollment). 4. Subjects who have previously received hyperthermia in conjunction with either radiation therapy or chemotherapy are eligible. 5. Subjects may have distant metastasis, including brain metastases. Subjects with known brain metastases are eligible if: - They have received standard anti-tumor treatment for their brain metastases without encephalopathy; - Their neurological function is stable for at least 30 days and either off steroid therapy or on a stable steroid regimen. 6. Non-pregnant female at least 18 years of age. If the subject is of child-bearing age, must have a negative serum pregnancy test at baseline and must agree to practice an acceptable form of birth control while on the study. 7. Provide written informed consent and willing to comply with protocol requirements. Exclusion Criteria: 1. Requires any concomitant antineoplastic therapy. Prior chemotherapy should not be administered within 5 half-lives or 28 days whichever is shorter. Subjects on a current stable dose of hormonal treatments may continue on a stable dose during the study (i.e. arimidex, amarosin, herceptin). 2. Prior confirmed allergic reaction (including moderate rash, dyspnea, wheezing, urticaria or other symptoms) attributed to the administration of either anthracyclines or other liposomally encapsulated drugs that required discontinuation of prior therapy. 3. Prior therapy with anthracyclines exceeding the following doses (subjects will be discontinued at 600 mg/m2 lifetime dose irrespective of the number of ThermoDox® cycles received): Free (i.e., non-liposomal) or liposomal doxorubicin > 450 mg/m2 Free epirubicin > 900 mg/m2. 4. Previous (required active treatment within 5 years) or concomitant malignancy except basal cell cancer, in situ carcinoma of the cervix, or contralateral breast cancer. Subjects with a prior contralateral breast malignancy can be included if they did not receive any chemotherapy. 5. Baseline laboratories (repeat labs can be evaluated at baseline to establish eligibility): - ANC Granulocytes < 1,500/ microliter - Platelets < 75,000/ microliter - Hemoglobin < 9 gm/dL - Total Bilirubin > 2 mg/dL - ALT and AST > 2.5 X upper limit of normal - Creatinine > 1.5 X upper limit of normal. 6. ECOG/Zubrod Performance Status > 2. 7. MUGA/Echocardiogram Left Ventricular Ejection Fraction < 50%. 8. Has a medical or psychiatric condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post-dose follow-up examinations. 9. History of: - Acute coronary syndrome - Cerebral vascular accident - Abnormal cardiac stress testing within last 6 months - Symptomatic coronary artery disease - Uncontrolled hypertension or cardiomyopathy - Cardiac valvular surgery or open heart surgery - Known structural heart disease. 10. Has a condition which may interfere with the hyperthermia portion of the trial such as: functioning cardiac pacemaker; metal plates, rods or prosthesis of the chest wall, breast reconstruction with implants, severe numbness and/or tingling of the chest wall or breast, skin grafts and/or flaps on the breast or chest wall. 11. Active infection requiring antibiotic treatment 12. Has received any external radiation therapy within 28 days prior to enrollment. |
Country | Name | City | State |
---|---|---|---|
United States | University of Maryland | Baltimore | Maryland |
United States | Southeastern Regional Medical Center | Newnan | Georgia |
United States | Eastern Regional Medical Center | Philadelphia | Pennsylvania |
United States | University of California, San Francisco | San Francisco | California |
United States | Washington University in St. Louis | St. Louis | Missouri |
United States | Southwestern Regional Medical Center | Tulsa | Oklahoma |
Lead Sponsor | Collaborator |
---|---|
Celsion |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To determine the bioequivalence of ThermoDox when used with hyperthermia among patients with RCW breast cancer. | PK collection at Cycle 1 and Cycle 2 | ||
Primary | To determine efficacy of ThermoDox in combination with Hyperthermia | Efficacy assessed at Cycle 3, Cycle 5 and End of Treatment | ||
Secondary | To evaluate the safety of ThermoDox in combination with Hyperthermia | Through 6 treatment Cycles |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |